Alvotech (ALVO): Firm Reaffirms 2025 Growth Outlook

Alvotech (NASDAQ:ALVO) is one of the Stocks That Could Mint Millionaires in 2026.

Alvotech (ALVO): Firm Reaffirms 2025 Growth Outlook

The firm recently launched a $100 million offering of senior unsecured convertible notes due 2030 and reaffirmed its 2025 outlook while providing initial guidance for 2026. In 2026, Alvotech anticipates total revenues in the range of $650-$700 million, reflecting continued sales growth. Adjusted EBITDA is expected to increase to $180-$220 million, supported by higher volumes of commercialized products and launches of newly approved products in Europe and Japan.

On November 12, Alvotech (NASDAQ:ALVO) posted third-quarter results, posting earnings per share of $0.47, beating estimates by $0.49. Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year. Product and service revenue increased by 85%, to $237 million in the first nine months compared to the same period last year, per the firm.

Alvotech (NASDAQ:ALVO) develops and manufactures biosimilar medicines for patients worldwide.

While we acknowledge the potential of ALVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALVO and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term

Disclosure: None.